- Home
- NRIX vs ECVT Comparison
NRIX vs ECVT Comparison
Compare NRIX & ECVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | ECVT |
|---|---|---|
| Founded | 2009 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRIX | ECVT |
|---|---|---|
| Price | $14.53 | $12.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $30.50 | $14.00 |
| AVG Volume (30 Days) | 961.1K | ★ 1.8M |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $76,987,000.00 | ★ $723,515,000.00 |
| Revenue This Year | N/A | $29.07 |
| Revenue Next Year | $48.05 | $6.71 |
| P/E Ratio | ★ N/A | $323.25 |
| Revenue Growth | ★ 99.31 | 2.70 |
| 52 Week Low | $8.20 | $7.39 |
| 52 Week High | $22.50 | $15.09 |
Technical Indicators
Market Signals| Indicator | NRIX | ECVT |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 36.84 |
| Support Level | $11.67 | $12.74 |
| Resistance Level | $17.06 | $15.01 |
| Average True Range (ATR) | 0.90 | 0.39 |
| MACD | -0.26 | -0.16 |
| Stochastic Oscillator | 3.88 | 1.00 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.